The U.S. Food and Drug Administration has recently approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes. The drugs Nesina tablets, Kazano tablets, and Oseni tablets have bee approved in hopes of treating the most common form of the disease. Type 2 diabetes affects about 24 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Individuals with type 2 diabetes are either resistant to insulin or do not produce enough insulin, resulting in high blood sugar levels. High blood sugar levels over a long period of time can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.
Nesina, Kazano, and Oseni were studied as stand-alone therapies as well as in combination with other type 2 diabetes therapies, including sulfonylureas and insulin. These drugs, however, should not be used to treat people with type 1 diabetes or those who have increased ketones in their blood or urine also known as diabetic ketoacidosis. Nesina was demonstrated to be safe and effective in 14 clinical trials involving about 8,500 patients with type 2 diabetes. The safety and efficacy of Kazano was demonstrated in four clinical trials involving more than 2,500 patients with type 2 diabetes. Oseni was demonstrated to be safe and effective in four clinical trials involving more than 1,500 patients with type 2 diabetes.
Nesina, Kazano, and Oseni are distributed by Takeda Pharmaceuticals America, Inc., Deerfield, Illinois.
Read more at FDA.gov